PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2021; 04(02): 59-63
DOI: 10.4103/jdep.jdep_4_21
Original Article

Phenotypes of high-density lipoprotein cholesterol and their relationship with glycemic status in type 2 diabetic patients

Chikezie Onwukwe
1   Division of Endocrinology and Diabetes, Al Isawiya General Hospital, Ministry of Health, Directorate of Gurayat
,
Nkiru Chikezie
2   Public Health Specialist, Department of Community Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra
,
Kalu Okorie
3   Consultant Cardiologist, Department of Medicine, Cedarcrest Hospitals, Gudu, Abuja
,
Augustine Ohwovoriole
4   Professor of Medicine and Consultant Endocrinologist, College of Medicine, University of Lagos, Lagos, Nigeria
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Background: There are varying reports on the association of high-density lipoprotein cholesterol (HDL-C) phenotypes and glycemia in type 2 diabetes mellitus (T2D) patients. Such information is lacking in Nigerian data. Aim: The aim of this study was to determine the relationship between HDL-C phenotypes and glycemic control in T2D patients. Materials and Methods: Clinical and laboratory data were collected from consenting T2D patients. Information was managed and analyzed with appropriate software. Results: Four hundred T2D patients consisting of 235 and 165 persons with and without poor glycemic control, respectively, were recruited for this study. There was a significant negative correlation between glycosylated hemoglobin (HbA1c) and the HDL2-C phenotype (rs = −0.12, P = 0.01). The correlation between HbA1c and the HDL3-C phenotype was not statistically significant (rs = −0.06, P = 0.21). Conclusion: The HDL2 phenotype has a stronger correlation with glycemic status than the HDL3 phenotype in T2D patients.

Keywords

Glycemic control - high-density lipoprotein - phenotype

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 02. März 2021

Angenommen: 01. April 2021

Artikel online veröffentlicht:
06. Juli 2022

© 2021. Gulf Association of Endocrinology and Diabetes (GAED). All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Valabhji J, Elkeles RS. Dyslipidaemia in type 2 diabetes: Epidemiology and biochemistry. Br J Diabetes Vascular Dis 2003;3:184-9.
  • 2 Link JJ, Rohatgi A, de Lemos JA. HDL cholesterol: Physiology, pathophysiology, and management. Curr Probl Cardiol 2007;32:268-314.
  • 3 Syvanne M, Ahola M, Lahdenpera S, Kahri J, Kuusi T, Virtanen KS, et al. High density lipoprotein subfractions in non-insulin dependent diabetes mellitus and coronary disease. J Lipid Res 1995;36:573-82.
  • 4 Gowri MS, van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999;19:2226-33.
  • 5 El-Nasri HA, Ahmed AM. Patterns of lipid changes among type 2 diabetes patients in Sudan. East Med Health J 2008;14:316-24.
  • 6 Agboola-Abu CF, Ohwovoriole AE, Akinlade KS. The effect of glycaemic control on the prevalence and pattern of dyslipidaemia in Nigerian patients with newly diagnosed non-insulin dependent diabetes mellitus. WAJM 2000;19:27-33.
  • 7 Okafor CI, Fasanmade OA, Oke DA. Pattern of dyslipidaemia among Nigerians with type 2 diabetes mellitus. Niger J Clin Pract 2008;11:25-31.
  • 8 Jisieike-Onuigbo NN, Unuigbe EI, Oguejiofor CO. Dyslipidemias in type 2 diabetes mellitus patients in Nnewi South-East Nigeria. Ann Afr Med 2011;10:285-9.
  • 9 Jimoh AK, Adediran OS, Agboola SM, Busari OA, Idowu A, Adeoye TA, et al. Lipid profile of type 2 diabetic patients at a rural tertiary hospital in Nigeria. J Diabetes Endocrinol 2010;1:46-51.
  • 10 Edo A, Adediran OS. Dyslipidaemia among Nigerian oil workers with type 2 diabetes mellitus. West Afr J Med 2011;30:206-9.
  • 11 WHO STEPS Instruments. Available from: http//www.who.int/chp/steps. [Last accessed on 2021 Feb 05].
  • 12 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.
  • 13 Marks V. An improved glucose oxidase method for determining blood, CSF, urine glucose levels. Clin Chim Acta 1996;251:19-24.
  • 14 Flückiger R, Woodtli T, Berger W. Quantitation of glycosylated hemoglobin by boronate affinity chromatography. Diabetes 1984;33:73-6.
  • 15 Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J Lipid Res 2008;49:1130-6.
  • 16 Husdan H, Rapoport A. Estimation of creatinine by the Jaffe reaction. A comparison of three methods. Clin Chem 1968;14:222-38.
  • 17 Bergmeyer HU, Hørder M. International federation of clinical chemistry. Scientific committee. Expert panel on enzymes. IFCC document stage 2, draft 1; 1979-11-19 with a view to an IFCC recommendation. IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase. J Clin Chem Clin Biochem 1980;18:521-34.
  • 18 Balasubramaniam P, Malathi A. Comparative study of hemoglobin estimated by Drabkin's and Sahli's methods. J Postgrad Med 1992;38:8-9.
  • 19 Kumar AA, Patton MR, Hennek JW, Lee SY, D'Alesio-Spina G, Yang X, et al. Density-based separation in multiphase systems provides a simple method to identify sickle cell disease. Proc Natl Acad Sci U S A 2014;111:14864-9.
  • 20 Logan JE, Bayse DD, Koedam JC, Mather A, Wilding P. International federation of clinical chemistry (IFCC). Scientific Committee, Analytical Section. IFCC/WHO principles and recommendations on evaluation of diagnostic reagent sets used in health laboratories with limited resources. Part 3. Selection and evaluation using reference materials. General considerations. J Clin Chem Clin Biochem 1984;22:573-82.
  • 21 International Diabetes Federation. Global Guideline for Type 2 Diabetes. International Diabetes Federation Guideline Development Group. Diabetes Res Clin Pract 2014;104:1-52.
  • 22 Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-37.
  • 23 World Health Organization. Worldwide Prevalence of Anemia 1993–2005. A Report of the Geneva: World Health Organization; 2008.
  • 24 Xian X, Ma Y, Yang DD, Huang W, Wang Y, Mueller O, et al. Reduced high-density lipoprotein 2b in non-obese type 2 diabetic patients analysed by a microfluidic chip method in a case-control study. Biomarkers 2009;14:619-23.
  • 25 Maeda S, Nakanishi S, Yoneda M, Awaya T, Yamane K, Hirano T, et al. Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans. J Atheroscler Thromb 2012;19:444-52.
  • 26 Paniagua JA, López-Miranda J, Jansen S, Zambrana JL, López Segura F, Jiménez Perepérez JA, et al. Increased high-density lipoprotein-3 binding to leukocytes following weight loss and improved glycemic control in type 2 diabetic patients. Metabolism 2000;49:692-7.
  • 27 Fukui T, Hirano T. High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without/with intensive insulin therapy. Endocr J 2012;59:561-9.
  • 28 Dong J, Guo H, Yang R, Li H, Wang S, Zhang J, et al. A novel and precise method for simultaneous measurement of serum HDL and LDL subfractions and lipoprotein (a) cholesterol by ultracentrifugation and high-performance liquid chromatography. Clin Chim Acta 2012;413:1071-6.